To evaluate whether African American (AA) men are at higher risk of reclassification in a large, prospective multi-institutional active surveillance (AS) cohort.
The Canary Prostate Active Surveillance Study (PASS) is a protocol-driven active surveillance cohort with pre-specified prostate-specific antigen (PSA) and surveillance biopsies regimen.
To report biopsy-related and oncologic outcomes in a large prospective active surveillance cohort that was initiated in the pre-MRI era and to additionally identify clinical factors associated with disease reclassification in order to inform future studies designed to improve enrollment and follow-up on AS.
There is uncertainty in deferred active treatment (DAT) programmes, regarding patient selection, follow-up and monitoring, reclassification, and which outcome measures should be prioritised.
To develop consensus statements for all domains of DAT.
Whether men with Gleason 3+4 prostate cancer are appropriate active surveillance (AS) candidates remains a matter of debate.
to evaluate the effects of initial Gleason grade 3+3 or 3+4 on clinical outcomes during AS.
Login to update email address, newsletter preferences and use bookmarks.